Moderna stock gains as insider sales and guidance stay in view

Published on 09/17/2026 at 10:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Moderna stock closed at USD 145.62 on September 16, 2026, while MarketBeat puts its consensus target at USD 76.72. The July 31 quarter showed EPS of -USD 1.97 on revenue of USD 145.0 million.

Isometrische 3D-Grafik zeigt Pharma-Wertschöpfungskette von Labor bis Krankenhaus — Moderna Inc. (US60770K1034) illustriert die isometrische Wertschöpfungskette der Biotech-Branche von Forschung bis zur finalen Auslieferung, Illustration mit AI erstellt.

Moderna Inc. (US60770K1034) stock closed at USD 145.62 on September 16, 2026, up 1.29 percent on the day, with a market capitalization of USD 58.14 billion and volume of 8.80 million shares. The gap to the MarketBeat consensus target is wide, and that keeps valuation in the center of the debate.

Analyst target stays low

According to MarketBeat, Moderna has a consensus rating of Hold, based on 7 Buy ratings, 12 Hold ratings and 5 Sell ratings, with an average price target of USD 76.72. That target implies about 47.3 percent downside from the closing price of USD 145.62 on September 16, 2026.

MarketBeat's chart page also shows a 52-week range of USD 22.28 to USD 176.66, so the stock is trading closer to the upper end of its annual band than to the low. The same page lists a year-to-date gain of 393.79 percent, which highlights how far the shares have run in 2026.

July 31 numbers matter

According to MarketBeat, Moderna last reported quarterly EPS of USD -1.97 on July 31, 2026, beating the consensus estimate by USD 0.06. The same source said revenue was USD 145.0 million, above the USD 102.93 million estimate, and that sales were up 2.1 percent year over year.

For investors, that mix matters more than the headline share price. Revenue beat estimates by USD 42.07 million, but the quarter still showed a loss, and that keeps the earnings path under scrutiny.

Insider selling adds pressure

According to StockTitan, Moderna President Stephen Hoge exercised options for 152,905 shares on September 14 and 15, 2026 at USD 12.21 per share and sold 80,575 shares at weighted average prices of USD 144.13 and USD 146.07. The filing puts the sale proceeds at about USD 11.69 million.

MarketBeat also says Moderna insiders sold USD 16.86 million worth of stock over the past three months, while institutions hold 75.33 percent of the shares. That combination leaves the market watching insider behavior alongside the next reporting step.

Price holds near highs

Moderna stock ended September 16, 2026 at USD 145.62, after trading between USD 142.30 and USD 148.93 that day. The share price was also about 17.5 percent below the 52-week high of USD 176.66 and about 556.2 percent above the 52-week low of USD 22.28.